Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
- 23 February 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 117 (8), 2307-2318
- https://doi.org/10.1182/blood-2010-10-265603
Abstract
Progress in the last decade has improved the understanding of leukemia biology. Molecular markers in combinations with cytogenetics have improved the risk stratification of acute myeloid leukemia (AML) and informed decision-making. In parallel, several important advances in the transplant field, such as better supportive care, improved transplant technology, increased availability of alternative donors, and reduced-intensity conditioning have improved the safety as well as access of allogeneic hematopoietic cell transplantation (HCT) for a larger number of patients. In this review, the positioning of HCT in the management of patients with AML is evaluated in view of changing risk/benefit ratios associated with both conventional treatments and transplantation, and some of the controversies are addressed in light of emerging data. Increasing data demonstrate outcomes of alternative donor transplantation approaching HLA-identical sibling donors in high-risk AML supporting the inclusion of alternative donors in trials of prospective studies evaluating post remission strategies for high-risk AML. The use of reduced-intensity conditioning has expanded the eligibility of HCT to older patients with AML, and outcome data are encouraging. Continued study of HCT versus alternative therapies is required to optimize patients' outcomes in AML. (Blood. 2011;117(8):2307-2318)This publication has 120 references indexed in Scilit:
- DNMT3AMutations in Acute Myeloid LeukemiaNew England Journal of Medicine, 2010
- Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced AgeTransplantation and Cellular Therapy, 2010
- Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysisThe Lancet Oncology, 2010
- Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remissionLeukemia, 2010
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Access to Hematopoietic Cell Transplantation in the United StatesTransplantation and Cellular Therapy, 2009
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJama-Journal Of The American Medical Association, 2009
- Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosisBritish Journal of Cancer, 2009
- Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersBlood, 2007
- Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic TransplantationTransplantation and Cellular Therapy, 2007